The Experts below are selected from a list of 5412 Experts worldwide ranked by ideXlab platform

Roswitha Dickerhoff - One of the best experts on this subject based on the ideXlab platform.

  • the clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment
    The Journal of Pediatrics, 2000
    Co-Authors: Roswitha Dickerhoff, Alexander Von Ruecker
    Abstract:

    Objective: To demonstrate the result of watchful waiting without specific therapy in unselected children with acute immune thrombocytopenic purpura (ITP). Study design: Between May 1992 and October 1999, 55 consecutive children (aged 2 months to 16 years; 28 boys and 27 girls) with acute ITP did not receive intravenously administered immune globulin G (IVIG) or sustained prednisone treatment. Patients with extensive Mucosal Bleeding were given prednisone, 2 mg/kg/d, for 3 days. Results: In 37 of 55 patients the initial platelet count was <10,000/μL. Ten of these patients had active Mucosal Bleeding. Five additional patients with Bleeding had platelet counts between 10,000 and 20,000/μL. Four patients were given a 3-day course of prednisone. Chronic ITP occurred in 7 (13%) of the patients; 29 patients achieved remission within 6 weeks, and 19 patients, between 6 weeks and 6 months. No life-threatening Bleeding occurred, and no patient died. Conclusion: Most children with severe thrombocytopenia do not have active Mucosal Bleeding. This management approach, which did not administer specific therapy, avoided side effects, reduced cost, and was effective. (J Pediatr 2000;137:629-32)

  • The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment
    The Journal of pediatrics, 2000
    Co-Authors: Roswitha Dickerhoff, Alexander Von Ruecker
    Abstract:

    Objective: To demonstrate the result of watchful waiting without specific therapy in unselected children with acute immune thrombocytopenic purpura (ITP). Study design: Between May 1992 and October 1999, 55 consecutive children (aged 2 months to 16 years; 28 boys and 27 girls) with acute ITP did not receive intravenously administered immune globulin G (IVIG) or sustained prednisone treatment. Patients with extensive Mucosal Bleeding were given prednisone, 2 mg/kg/d, for 3 days. Results: In 37 of 55 patients the initial platelet count was

Alexander Von Ruecker - One of the best experts on this subject based on the ideXlab platform.

  • the clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment
    The Journal of Pediatrics, 2000
    Co-Authors: Roswitha Dickerhoff, Alexander Von Ruecker
    Abstract:

    Objective: To demonstrate the result of watchful waiting without specific therapy in unselected children with acute immune thrombocytopenic purpura (ITP). Study design: Between May 1992 and October 1999, 55 consecutive children (aged 2 months to 16 years; 28 boys and 27 girls) with acute ITP did not receive intravenously administered immune globulin G (IVIG) or sustained prednisone treatment. Patients with extensive Mucosal Bleeding were given prednisone, 2 mg/kg/d, for 3 days. Results: In 37 of 55 patients the initial platelet count was <10,000/μL. Ten of these patients had active Mucosal Bleeding. Five additional patients with Bleeding had platelet counts between 10,000 and 20,000/μL. Four patients were given a 3-day course of prednisone. Chronic ITP occurred in 7 (13%) of the patients; 29 patients achieved remission within 6 weeks, and 19 patients, between 6 weeks and 6 months. No life-threatening Bleeding occurred, and no patient died. Conclusion: Most children with severe thrombocytopenia do not have active Mucosal Bleeding. This management approach, which did not administer specific therapy, avoided side effects, reduced cost, and was effective. (J Pediatr 2000;137:629-32)

Jeroen C. J. Eikenboom - One of the best experts on this subject based on the ideXlab platform.

  • Von Willebrand’s Disease
    The New England Journal of Medicine, 2016
    Co-Authors: Frank W.g. Leebeek, Jeroen C. J. Eikenboom
    Abstract:

    Von Willebrand's disease is the most common inherited Bleeding disorder and is generally transmitted as an autosomal dominant trait. It is mainly associated with Mucosal Bleeding and excessive Bleeding after trauma or surgery. A variety of effective treatments are available.

  • von willebrand s disease
    The New England Journal of Medicine, 2016
    Co-Authors: Frank W.g. Leebeek, Jeroen C. J. Eikenboom
    Abstract:

    Von Willebrand's disease is the most common inherited Bleeding disorder and is generally transmitted as an autosomal dominant trait. It is mainly associated with Mucosal Bleeding and excessive Bleeding after trauma or surgery. A variety of effective treatments are available.

Alexander Von Ruecker - One of the best experts on this subject based on the ideXlab platform.

Frank W.g. Leebeek - One of the best experts on this subject based on the ideXlab platform.

  • Von Willebrand’s Disease
    The New England Journal of Medicine, 2016
    Co-Authors: Frank W.g. Leebeek, Jeroen C. J. Eikenboom
    Abstract:

    Von Willebrand's disease is the most common inherited Bleeding disorder and is generally transmitted as an autosomal dominant trait. It is mainly associated with Mucosal Bleeding and excessive Bleeding after trauma or surgery. A variety of effective treatments are available.

  • von willebrand s disease
    The New England Journal of Medicine, 2016
    Co-Authors: Frank W.g. Leebeek, Jeroen C. J. Eikenboom
    Abstract:

    Von Willebrand's disease is the most common inherited Bleeding disorder and is generally transmitted as an autosomal dominant trait. It is mainly associated with Mucosal Bleeding and excessive Bleeding after trauma or surgery. A variety of effective treatments are available.

  • Prophylaxis escalation in severe von Willebrand disease: a prospective study from the von Willebrand Disease Prophylaxis Network.
    Journal of thrombosis and haemostasis : JTH, 2015
    Co-Authors: Thomas C. Abshire, Frank W.g. Leebeek, J. Cox-gill, Christine L. Kempton, Manuel Carcao, Peter A. Kouides, Sharyne M. Donfield, Erik Berntorp
    Abstract:

    Treatment of Mucosal Bleeding (epistaxis, gastrointestinal and menorrhagia) and joint Bleeding remains problematic in clinically severe von Willebrand Disease (VWD). Patients are often unresponsive to treatment (e.g. desmopressin or antifibrinolytic therapy) and may require von Willebrand (VW) factor replacement therapy. There are little data on the use of prophylaxis in VWD and none applied in a prospective, treatment escalation design.